Hematology: Rituximab for follicular lymphoma: Maintaining an open mind

Nature Reviews Clinical Oncology

Volumn 8, Issue 5, 2011, Pages 257-258

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GALIXIMAB; IFOSFAMIDE; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; VINCRISTINE;

ADVERSE OUTCOME; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG USE; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, FOLLICULAR; SURVIVAL RATE;

EID: 79955581576     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.35     Document Type: Article

References (10)

1. Flowers, C. et al. Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a8100 (2010).
2. Salles, G. et al. Rituximab manitenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42-51 (2011).
3. Martinelli, G. et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J. Clin. Oncol. 28, 4480-4484 (2010).
4. Ardeshna, K. M. et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis [abstract]. Blood 116, a6 (2010).
5. Hochster, H. et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progession-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J. Clin. Oncol. 27, 1607-1614 (2009).
6. van Oers, M. H. et al. Rituximab maintenance treatment of relapsed/resistant follicular non- Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J. Clin. Oncol. 28, 2853-2858 (2010).
7. Hainsworth, J. D. et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23, 1088-1095 (2005). (Pubitemid 46202263)
8. van Oers, M. H. et al. Rituximab maintenance improves clinical outcome of relapsed/ resistant follicular non-Hodgkin's lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108, 3295-3301 (2006). (Pubitemid 44794222)
9. Forstpointner, R. et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108, 4003-4008 (2006). (Pubitemid 44920177)
10. Gisselbrecht, C. et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study [abstract 8509]. J. Clin. Oncol. 27, 436s (2009).